Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective cohort study, researchers found that persistent discontinuation of gender-affirming hormones among transgender adolescents was rare, mainly due to achieving gender expression goals or access issues, with very few reidentifying with their birth-assigned sex.

This case report describes the use of individualized homoeopathic treatment and dietary modifications to manage hypothyroidism in a 23-year-old woman, resulting in symptom improvement and normalized TSH levels after tapering off levothyroxine.

Finasteride discontinuation increases sperm count in men.

This review highlights the possible impact of side effects from endocrine therapy on quality of life, emphasizing that these can lead to poor adherence and early treatment discontinuation in patients with hormone receptor positive early breast cancer, potentially worsening survival outcomes.

This systematic review suggests that current evidence does not support routinely discontinuing gender-affirming hormone treatments before surgery, especially testosterone and spironolactone, due to limited data on related perioperative risks.

This study found that discontinuing finasteride led to a significant increase in sperm counts for most men with reduced fertility, though hormone levels and other semen parameters remained unchanged.

Hormonal treatment in transgender women reduces semen quality, but stopping treatment may improve it.

This study highlights that scalp hair loss is an underreported side effect of somatostatin analogs therapy, potentially linked to decreased GH/IGF-1 levels or a direct drug effect.

This case study reported a rare and delayed onset of alopecia in a patient after paclitaxel chemotherapy, potentially influenced by the interaction of thyroid hormones and chemotherapy affecting hair follicle cycles.

This abstract lists keywords related to various medications and therapies, but it does not provide new study results or findings.

This case study describes a child with rickets and alopecia who responded to a small dose of 1-a-hydroxyvitamin D3, but her alopecia remained unchanged despite treatment.

This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.

In this case report, a 36-year-old woman was diagnosed with iatrogenic Cushing Syndrome caused by topical steroid use, leading to skin ulcers, diabetes, and anemia. Her condition improved after discontinuing the steroids and receiving appropriate treatment.

In this case report, a 25-year-old transgender woman on testosterone-blocking therapy developed generalised hypertrichosis after starting ciclosporin for severe plaque psoriasis, illustrating that ciclosporin can induce this side effect even under androgen suppression.

Testosterone undecanoate caused hair loss; finasteride improved it but caused stomach issues for one patient.

This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.

The researchers reported that finasteride was effective in controlling hormone-related dysfunction in an adult dog diagnosed with benign prostatic hyperplasia, although the condition regressed after the medication was withdrawn.

This report details a case of hair, nail, and pigmentary disorders occurring 10 months after starting abemaciclib for metastatic breast cancer, highlighting that cutaneous side effects, although less frequent, can lead to discontinuation in 25% of cases.

This review reports that 5-alpha reductase inhibitors, used to treat androgenic alopecia, may adversely affect sperm count, sexual function, and hormones in a subset of patients.

In this case study, biotin supplementation was reported to interfere with free testosterone assay results, leading to falsely low readings in a postmenopausal woman with hyperandrogenism.

This review describes drug-induced gynecomastia, which results from an imbalance between estrogen and androgen action, listing potential treatments but no new clinical results.

This study found that finasteride treatment in males with androgenetic alopecia was linked to significant changes in sperm parameters and increased testosterone levels, but no sexual dysfunction was observed, and sperm parameters returned to baseline after treatment stopped.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

This review examines hormonal influences on acne development and available hormonal therapies but reports no new clinical results.

This review discusses the potential link between long-term transdermal exposure to sex hormones from antiperspirants and increased breast and prostate cancer rates, calling for further research to confirm this theory.

This study found that experienced Australian prescribers of hormone therapy for transgender adults often follow international guidelines but highlight the need for better training and specific local guidelines.

This review discusses the effects and selection criteria of different progestogens in various treatments but reports no direct clinical comparisons of their metabolic effects.

This review discusses the role of androgens in women's sexual health and highlights the need for further research on androgen replacement therapy to optimize quality of life, but reports no new clinical results.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.